Biocept's Blood-based Liquid Biopsy for Non-small Cell Lung Carcinoma Highlighted in American Society of Clinical Oncology (ASCO) Abstract
Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, continues to build evidence of the clinical utility of its liquid biopsy offerings with an abstract at the 2015 Annual American Society of Clinical Oncology Meeting in Chicago starting on May 29, 2015.
Biocept offers a sensitive and quantitative blood-based method for the detection and monitoring of clinically actionable cancer biomarkers in order to help doctors make treatment decisions based on genomic information gained from the tumor material. The Company is engaged in multiple clinical studies designed to demonstrate the utility of its liquid biopsy diagnostic to detect a patient’s biomarker status and for the assessment of treatment response over time.
The abstract demonstrates the clinical utility of a liquid biopsy using Biocept’s technology, not only for a patient where there is insufficient tissue from a biopsy, but also in order to better represent a patient’s biomarker status by avoiding challenges associated with tissue heterogeneity, all accomplished with a simple blood draw.
"By providing oncologists such as myself with genomic testing results performed on a simple blood test, we are able to stratify patients based on biomarker status in real-time, which has the potential to drastically change how patients with solid cancers such as non-small cell lung cancers (NSCLC) are monitored," stated Dr. Lyudmila Bazhenova, MD, Associate Clinical Professor of Medicine at University of California, San Diego Moores Cancer Center.
"The ease of real-time monitoring and early identification of the emergence of resistance reduces the time to make a treatment change, which in a setting of metastatic cancer, is crucial. Additionally, the health economic benefit of obtaining actionable biomarker status from a simple blood draw in lieu of a surgical procedure is an added advantage to our health care system,” stated Veena Singh, MD, Sr. VP and Medical Director at Biocept.
The abstract also highlights the Biocept platform’s ability to provide subsequent serial monitoring of biomarker status after therapy to monitor clinical response as well as progression. “This is an important feature of the platform,” noted Dr. Singh. “Emerging therapies such as rociletinib and AZD9291 are in advanced clinical development and have been shown to benefit patients with T790M mutations, another biomarker associated with lung cancer. As the next-generation of therapies come to market, it will be important that clinicians have a method to perform serial monitoring on patients in order to understand when they are candidates for these therapies. At Biocept, we offer a test to detect these biomarkers.”
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers OncoCEE-GA™ for gastric cancer, OncoCEE-BR™ for breast cancer and OncoCEE-LU™ for non-small cell lung cancer, and plans to introduce CLIA-validated tests for colorectal, prostate and other solid tumors in the near term.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to improvement of outcomes, our impact on diagnostic strategies and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.